MarketPeel
Insider Trading Intelligence
Pricing
…
TD

Todd C. Davis

LGND
CHIEF EXECUTIVE OFFICER · LIGAND PHARMACEUTICALS INC · CIK 0001392029
FILING MIX · LIFETIME70%/30%
BUYS
44
SELLS
19
TOTAL VALUE
$28.08M
COMPANIES
3
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
128,892
AVG SELL PX
$166.79
TRADE KIND
SHOWING 63 / 63
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 4 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Todd C. Davis, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+100.00%-3.57%+3.33%-6.90%-5.23%—
14d6+33.33%-5.59%+2.15%-7.74%-5.37%—
30d6+83.33%-2.70%+3.22%-5.92%-1.48%—
60d6+83.33%+0.69%+8.05%-7.36%-0.59%—
90d6+100.00%+20.42%+10.77%+9.65%+18.82%—
180d6+100.00%+40.59%+18.37%+22.22%+34.50%—
1y6+100.00%+70.20%+27.31%+42.89%+60.70%—
2y6(4 pending)+100.00%+61.14%+32.88%+28.27%+28.27%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LGND · 50,058 shares · as of Mar 2, 2026
053,396106,793160,189213,585202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 44 buys / 19 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASE
503$28.73$14.4K75,834Jun 11, 2026Jun 15, 2026 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASE
35,445$27.80$985.5K75,331Jun 11, 2026Jun 15, 2026 ↗View →
PVLA
PALVELLA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,000——3,000Jun 10, 2026Jun 12, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
10,495——199,381Mar 2, 2026Mar 27, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
50,058——50,058Mar 2, 2026Mar 27, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
2,039$183.83$374.8K195,946Feb 15, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
4,255$183.83$782.2K191,691Feb 15, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
2,805$183.83$515.6K188,886Feb 15, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
20,782——182,119Feb 14, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
15,600$183.83$2.87M197,985Feb 14, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
39,644——213,585Feb 14, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
8,178$183.83$1.50M173,941Feb 14, 2026Feb 18, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALEGRANT
Gift
130——161,337Dec 4, 2025Dec 8, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
58,230——58,230Jul 2, 2025Jul 7, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
19,108——36,969Jul 2, 2025Jul 7, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
19,108——39,886Jul 2, 2025Apr 1, 2026 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASE
31,278.681——3,127,868Jul 1, 2025Jul 3, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
SALE
15,000——3,000Jul 1, 2025Jul 3, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASE
1,500,000$10.00$15.00M1,500,000Jul 1, 2025Jul 3, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
233$91.08$21.2K161,467Jun 30, 2025Jul 2, 2025 ↗View →
PVLA
PALVELLA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,350——12,350Jun 10, 2025Jun 11, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
1,680$104.57$175.7K153,404May 9, 2025May 13, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
2,307$104.53$241.1K155,711May 9, 2025May 13, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
5,523$105.67$583.6K161,234May 9, 2025May 13, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
21,382——151,724Mar 4, 2025Mar 6, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
93,476——93,476Mar 4, 2025Mar 6, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
2,231$120.00$267.7K134,597Feb 15, 2025Feb 19, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
4,255$120.00$510.6K130,342Feb 15, 2025Feb 19, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
20,784——143,794Feb 14, 2025Feb 19, 2025 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
6,966$120.00$835.9K136,828Feb 14, 2025Feb 19, 2025 ↗View →
PVLA
PALVELLA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,700——24,700Dec 13, 2024Dec 17, 2024 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
4,961——20,778Nov 13, 2024Apr 1, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
2,500$97.39$243.5K123,010Aug 8, 2024Aug 9, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
350$60.71$21.2K120,510Jun 28, 2024Jul 2, 2024 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
12,900——15,817Jun 14, 2024Apr 1, 2026 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
3,556$66.19$235.4K120,160Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
2,156——0Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
2,156$68.51$147.7K116,604Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
7,448$46.20$344.1K111,593Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
3,556——0Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
2,855——0Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
Chief Executive Officer
2,855$67.24$192.0K114,448Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
Chief Executive Officer
7,448——0Mar 25, 2024Mar 27, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
32,436——104,145Feb 27, 2024Feb 29, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
131,723——131,723Feb 27, 2024Feb 29, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
CHIEF EXECUTIVE OFFICER
1,381$74.65$103.1K71,709Feb 15, 2024Feb 16, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
CHIEF EXECUTIVE OFFICER
4,000$59.38$237.5K73,090Sep 22, 2023Sep 25, 2023 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
CHIEF EXECUTIVE OFFICER
420$73.76$31.0K69,090Jun 9, 2023Jun 13, 2023 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
17,005——68,791Feb 23, 2023Feb 27, 2023 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
46,178——46,178Feb 23, 2023Feb 27, 2023 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
2,081——2,081Dec 22, 2022Dec 27, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
132,000——132,000Dec 5, 2022Dec 6, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,004——51,786Jun 10, 2022Jun 13, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
4,340——4,340Jun 10, 2022Jun 13, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3,269——3,269Jun 4, 2021Jun 7, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
630——50,782Jun 4, 2021Jun 7, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
2,474——0Feb 11, 2021Feb 12, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
2,474$195.91$484.7K50,152Feb 11, 2021Feb 12, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
5,083$213.14$1.08M47,678Feb 10, 2021Feb 12, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
2,456——0Jan 27, 2021Jan 27, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASE
2,456$113.50$278.8K52,761Jan 27, 2021Jan 27, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
2,468——2,468Jun 10, 2020Jun 12, 2020 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
831——50,305Jun 10, 2020Jun 12, 2020 ↗View →
Other insiders · LGND
Loading peer insiders…
About this filer
CIK 0001392029
ROLE
Chief Executive Officer
PRIMARY
LGND
COMPANIES
3
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001392029DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback